Rani Therapeutics Holdings, Inc. Major Shareholder Sells 10,582,981.65 in Stock
RANI Stock | USD 2.02 0.03 1.51% |
Under 59% of all Rani Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that some traders are interested. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
Rani |
Rani Therapeutics Holdings, Inc. major shareholder Cortes Isidoro Alfonso Quiroga sold 5,265,165 shares of the firms stock in a transaction dated Friday, November 24th. The stock was sold at an average price of 2.01, for a total transaction of 10,582,981.65. Following the completion of the sale, the insider now owns
Read at thelincolnianonline.com
Rani Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
RANI: 1Q:24 Results
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rani Therapeutics Fundamental Analysis
We analyze Rani Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Rani Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Rani Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rani Therapeutics stock to make a market-neutral strategy. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics with similar companies.
Peers
Rani Therapeutics Related Equities
CABA | Cabaletta Bio | 26.91 | ||||
SRZN | Surrozen | 19.37 | ||||
GLUE | Monte Rosa | 13.72 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
MNPR | Monopar Therapeutics | 8.84 | ||||
TNYA | Tenaya Therapeutics | 8.51 | ||||
VINC | Vincerx Pharma | 7.69 | ||||
BMEA | Biomea Fusion | 3.13 | ||||
VCNX | Vaccinex | 2.44 | ||||
TRVI | Trevi Therapeutics | 2.13 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
MOLN | Molecular Partners | 0.17 | ||||
TARA | Protara Therapeutics | 0.99 | ||||
ALXO | Alx Oncology | 1.99 | ||||
TYRA | Tyra Biosciences | 2.00 | ||||
PHVS | Pharvaris | 2.06 | ||||
EYPT | Eyepoint Pharmaceuticals | 2.21 | ||||
CRVS | Corvus Pharmaceuticals | 3.50 | ||||
VIRX | Viracta Therapeutics | 6.67 |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |